UY34409A - Inmunoenlazadores dirigidos contra el tnf - Google Patents
Inmunoenlazadores dirigidos contra el tnfInfo
- Publication number
- UY34409A UY34409A UY0001034409A UY34409A UY34409A UY 34409 A UY34409 A UY 34409A UY 0001034409 A UY0001034409 A UY 0001034409A UY 34409 A UY34409 A UY 34409A UY 34409 A UY34409 A UY 34409A
- Authority
- UY
- Uruguay
- Prior art keywords
- immuno
- against tnf
- linkers
- linkers against
- tnf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Abstract
Se describen proteínas de enlace, por ejemplo anticuerpos o porciones de enlace al antígeno de los mismos, los cuales se enlazan al factor de necrosis de tumores alfa (TNF-a), por ejemplo el TNF-a humano, y composiciones y moléculas relacionadas basadas en el anticuerpo. También se describen composiciones farmacéuticas que comprenden los anticuerpos, así como métodos terapéuticos y métodos de dia gnóstico para usar los anticuerpos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550587P | 2011-10-24 | 2011-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34409A true UY34409A (es) | 2013-05-31 |
Family
ID=47144149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034409A UY34409A (es) | 2011-10-24 | 2012-10-24 | Inmunoenlazadores dirigidos contra el tnf |
Country Status (25)
Country | Link |
---|---|
US (2) | US9803009B2 (es) |
EP (1) | EP2771362A1 (es) |
JP (1) | JP2014534218A (es) |
KR (1) | KR20140084253A (es) |
CN (1) | CN104093739A (es) |
AR (1) | AR088512A1 (es) |
AU (1) | AU2012328921B2 (es) |
BR (1) | BR112014009799A2 (es) |
CA (1) | CA2853357A1 (es) |
CL (1) | CL2014001054A1 (es) |
CO (1) | CO7020873A2 (es) |
CR (1) | CR20140225A (es) |
DO (1) | DOP2014000083A (es) |
EC (1) | ECSP14001249A (es) |
HK (1) | HK1200464A1 (es) |
IL (1) | IL232129A0 (es) |
IN (1) | IN2014CN03936A (es) |
MX (1) | MX2014004981A (es) |
PE (1) | PE20141545A1 (es) |
RS (1) | RS20140203A1 (es) |
RU (1) | RU2014120755A (es) |
SG (1) | SG11201401774VA (es) |
TW (1) | TW201326207A (es) |
UY (1) | UY34409A (es) |
WO (1) | WO2013063114A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012002605A (es) | 2009-08-29 | 2012-04-02 | Abbott Lab | Proteinas terapeutico de union a dll4. |
BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
UY34410A (es) | 2011-10-24 | 2013-05-31 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
CN104203978A (zh) | 2011-10-24 | 2014-12-10 | 艾伯维股份有限公司 | 针对硬化蛋白的免疫结合剂 |
US9803009B2 (en) | 2011-10-24 | 2017-10-31 | Abbvie Inc. | Immunobinders directed against TNF |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US9458244B2 (en) | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
US9915665B2 (en) | 2012-12-28 | 2018-03-13 | Abbvie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
JP6526025B2 (ja) | 2013-10-16 | 2019-06-05 | オンコバイオロジクス,インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
WO2015191760A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
EP3350217A4 (en) * | 2015-09-14 | 2019-09-04 | Galaxy Biotech LLC | HIGHLY POWERFUL MONOCLONAL ANTIBODIES AGAINST ANGIOGENIC FACTORS |
WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
AU2017213775A1 (en) | 2016-02-03 | 2018-08-16 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
AU2017274442B2 (en) | 2016-06-02 | 2021-08-19 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
US11484507B2 (en) | 2016-11-02 | 2022-11-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles providing nucleic acids encoding TNF-α |
CN107903323B (zh) * | 2017-11-15 | 2020-04-17 | 中国药科大学 | 抗hTNF-α全人源抗体及其用途 |
EP3884962A1 (en) | 2017-12-01 | 2021-09-29 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
WO2023205739A2 (en) * | 2022-04-20 | 2023-10-26 | Senti Biosciences, Inc. | Antigen-binding domains and methods of use thereof |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US6114147A (en) | 1993-02-10 | 2000-09-05 | Unilever Patent Holdings | Immobilized proteins with specific binding capacities and their use in processes and products |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JPH11503914A (ja) | 1995-04-21 | 1999-04-06 | セル ジェネシス,インコーポレイテッド | 大ゲノムdna欠失の生成 |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
WO2003029456A1 (en) | 2001-10-01 | 2003-04-10 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
ES2347239T3 (es) | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
WO2004063335A2 (en) | 2003-01-08 | 2004-07-29 | Applied Molecular Evolution | TNF-α BINDING MOLECULES |
EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
WO2006014477A1 (en) * | 2004-07-06 | 2006-02-09 | Bioren, Inc. | HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
BRPI0809026A2 (pt) | 2007-03-20 | 2014-09-23 | Lilly Co Eli | Anticorpos antiesclerotina |
AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
NZ600979A (en) | 2008-01-15 | 2014-01-31 | Abbott Lab | Improved mammalian expression vectors and uses thereof |
NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2403531A4 (en) | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
RU2012147249A (ru) | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
CN104203978A (zh) | 2011-10-24 | 2014-12-10 | 艾伯维股份有限公司 | 针对硬化蛋白的免疫结合剂 |
US9803009B2 (en) | 2011-10-24 | 2017-10-31 | Abbvie Inc. | Immunobinders directed against TNF |
UY34410A (es) | 2011-10-24 | 2013-05-31 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
PE20151670A1 (es) | 2013-03-15 | 2015-12-12 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra tnf-alfa |
-
2012
- 2012-10-24 US US13/659,658 patent/US9803009B2/en not_active Expired - Fee Related
- 2012-10-24 EP EP12783475.2A patent/EP2771362A1/en not_active Withdrawn
- 2012-10-24 RU RU2014120755/10A patent/RU2014120755A/ru not_active Application Discontinuation
- 2012-10-24 KR KR1020147013794A patent/KR20140084253A/ko not_active Application Discontinuation
- 2012-10-24 BR BR112014009799A patent/BR112014009799A2/pt unknown
- 2012-10-24 WO PCT/US2012/061690 patent/WO2013063114A1/en active Application Filing
- 2012-10-24 IN IN3936CHN2014 patent/IN2014CN03936A/en unknown
- 2012-10-24 PE PE2014000587A patent/PE20141545A1/es not_active Application Discontinuation
- 2012-10-24 UY UY0001034409A patent/UY34409A/es not_active Application Discontinuation
- 2012-10-24 CA CA2853357A patent/CA2853357A1/en not_active Abandoned
- 2012-10-24 TW TW101139327A patent/TW201326207A/zh unknown
- 2012-10-24 CN CN201280064311.3A patent/CN104093739A/zh active Pending
- 2012-10-24 JP JP2014538927A patent/JP2014534218A/ja active Pending
- 2012-10-24 AR ARP120103977A patent/AR088512A1/es unknown
- 2012-10-24 MX MX2014004981A patent/MX2014004981A/es unknown
- 2012-10-24 RS RS20140203A patent/RS20140203A1/en unknown
- 2012-10-24 AU AU2012328921A patent/AU2012328921B2/en not_active Ceased
- 2012-10-24 SG SG11201401774VA patent/SG11201401774VA/en unknown
-
2013
- 2013-11-06 US US14/073,479 patent/US20140170152A1/en not_active Abandoned
-
2014
- 2014-04-13 IL IL232129A patent/IL232129A0/en unknown
- 2014-04-24 CL CL2014001054A patent/CL2014001054A1/es unknown
- 2014-04-24 DO DO2014000083A patent/DOP2014000083A/es unknown
- 2014-05-14 CR CR20140225A patent/CR20140225A/es unknown
- 2014-05-19 EC ECIEPI20141249A patent/ECSP14001249A/es unknown
- 2014-05-22 CO CO14110749A patent/CO7020873A2/es unknown
-
2015
- 2015-01-22 HK HK15100709.5A patent/HK1200464A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014009799A2 (pt) | 2017-06-13 |
JP2014534218A (ja) | 2014-12-18 |
AU2012328921A8 (en) | 2014-05-08 |
CA2853357A1 (en) | 2013-05-02 |
IL232129A0 (en) | 2014-05-28 |
MX2014004981A (es) | 2014-09-11 |
AU2012328921A1 (en) | 2014-05-01 |
US20130164256A1 (en) | 2013-06-27 |
EP2771362A1 (en) | 2014-09-03 |
WO2013063114A1 (en) | 2013-05-02 |
CN104093739A (zh) | 2014-10-08 |
ECSP14001249A (es) | 2015-07-31 |
AR088512A1 (es) | 2014-06-18 |
CR20140225A (es) | 2014-08-04 |
KR20140084253A (ko) | 2014-07-04 |
CO7020873A2 (es) | 2014-08-11 |
AU2012328921B2 (en) | 2017-05-11 |
PE20141545A1 (es) | 2014-11-26 |
US9803009B2 (en) | 2017-10-31 |
RS20140203A1 (en) | 2014-10-31 |
HK1200464A1 (en) | 2015-08-07 |
DOP2014000083A (es) | 2014-06-15 |
CL2014001054A1 (es) | 2014-09-05 |
SG11201401774VA (en) | 2014-10-30 |
WO2013063114A8 (en) | 2014-03-20 |
RU2014120755A (ru) | 2015-12-10 |
TW201326207A (zh) | 2013-07-01 |
IN2014CN03936A (es) | 2015-09-04 |
US20140170152A1 (en) | 2014-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34409A (es) | Inmunoenlazadores dirigidos contra el tnf | |
UY34411A (es) | Inmunoenlazantes dirigidos contra esclerostina | |
UY34410A (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
CO7020912A2 (es) | Inhibidores de bromodominios | |
IN2014CN02639A (es) | ||
CO7111289A2 (es) | Compuestos inhibidores de metaloenzimas | |
UY34456A (es) | Anticuerpos anti-il-36r | |
UY34206A (es) | Anticuerpo monoclonal de interleucina-31 | |
CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
BR112013028512A2 (pt) | cápsula | |
UY34074A (es) | Composición oftálmica de olopatadina altamente concentrada | |
UY34582A (es) | Anticuerpos anti-cxcr3 | |
BR112014003027A2 (pt) | formulação herbicida melhorada | |
BR112014026634A2 (pt) | direcionador | |
UY34158A (es) | Composicion herbicida | |
CL2011002403S1 (es) | Luminaria solar. | |
BR112014029156A2 (pt) | arma curta curvada | |
UY34286A (es) | Diagnóstico de vacuna mejorado | |
UY34403A (es) | Preparación de liberación sostenida | |
CL2011002741S1 (es) | Reposera. | |
ES1072600Y (es) | Consolador sexual | |
UY33996A (es) | Preparacion sólida | |
TN2011000420A1 (fr) | طريقة علمية لمقاومة التصحر وتخصيب الصحراء | |
TN2011000287A1 (fr) | حذاء مولد للطاقة | |
TN2010000578A1 (fr) | خلاط مياه بثلاث صمامات |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201020 |